# Utility of Axillary Staging in Older Patients with HER2-Positive Breast Cancer.

**Autores:** Dalton JC, Crowell KA, Ntowe KW et al.
**Revista:** Ann Surg Oncol (2024)
**PMID:** 39014162 | **PMCID:** PMC11452275
**DOI:** [10.1245/s10434-024-15812-w](https://doi.org/10.1245/s10434-024-15812-w)
**Fuente:** PubMed Central (open access)

## Relevancia
Análisis de respuesta axilar y conversión a ypN0 en cáncer de mama HER2+ tratado con quimioterapia neoadyuvante anti-HER2; relevante para definir candidatas a desescalada quirúrgica axilar.

## Abstract
The utility of sentinel lymph node biopsy (SLNB) in older patients remains controversial. Advancements in human epidermal growth factor receptor 2 (HER2)-directed therapy have revolutionized disease response rates and prognosis, supporting efforts to re-evaluate the utility of SLNB. We aimed to assess the differences in treatment and overall survival (OS) in older patients with HER2-positive breast cancer based on SLNB.

Using the National Cancer Database (2010-2020), patients &#x2265; 70&#xa0;years of age diagnosed with cT1-2/cN0/M0, HER2-positive breast cancer were identified. Logistic regression assessed associations with SLNB, systemic therapy, and radiation. Cox proportional hazard models were used to identify factors associated with OS. Analyses were stratified by treatment sequence, i.e. upfront surgery or neoadjuvant therapy (NAT) followed by surgery.

Of the 17,609 patients included, 94% underwent upfront surgery (n&#xa0;=&#xa0;16,492) and the remaining underwent NAT (n&#xa0;=&#xa0;1117). Those who underwent SLNB were more likely to receive adjuvant therapy, irrespective of nodal status {upfront surgery/systemic therapy (odds ratio [OR] 2.82, 95% confidence interval [CI] 2.17-3.67); upfront surgery/radiation (OR 3.97, 95% CI 3.03-5.21); NAT/radiation (OR 5.69, 95% CI 1.83-17.69)}. The breast pathologic complete response (pCR) rate was highest among the hormone receptor (HR)-negative/HER2-positive subtype (50.0%), of which none were found to be ypN+. Comorbidity burden was associated with significantly lower rates of adjuvant systemic therapy and worse OS.

Patients who underwent SLNB, regardless of pN status, were more likely to receive adjuvant therapy. Nodal positivity is exceedingly rare for patients with a breast pCR following NAT, especially among the HR-negative/HER2-positive subtype. It is reasonable to consider omission of SLNB in select subgroups of older patients with HER2-positive breast cancer.

## Acceso
Disponible en PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11452275/

---
*Datos de PubMed. Citar: doi 10.1245/s10434-024-15812-w*
